 |
|
Quality-of-Life Assessment After Supradose Selective Intra-arterial Cisplatin and Concomitant Radiation (RADPLAT) for Inoperable Stage IV Head and Neck Squamous Cell Carcinoma
Annemieke H. Ackerstaff, PhD;
I. Bing Tan, MD, PhD;
Coen R. N. Rasch, MD, PhD;
Alfons J. M. Balm, MD, PhD;
Ronald B. Keus, MD;
Jan H. Schornagel, MD, PhD;
Frans J. M. Hilgers, MD, PhD
Arch Otolaryngol Head Neck Surg. 2002;128:1185-1190.
ABSTRACT
| |
Objective To evaluate quality-of-life (QOL) aspects of an organ preservation intra-arterial
chemotherapy and concomitant radiation protocol, RADPLAT.
Design Nonrandomized phase 2B feasibility trial.
Patients Fifty consecutive patients with inoperable stage IV head and neck cancer.
Intervention Supradose selective intra-arterial cisplatin and concomitant standard
radiation (RADPLAT).
Measures Assessment with structured questionnaires before treatment and at 3,
6, and 12 months.
Results Twenty-six patients were available for QOL assessment at 1 year (the
"1-year QOL" group), as 16 patients died, 5 needed salvage surgery, and 3
were not available for interview (the "failure" group). Twelve-month results
were mainly based on the first group. The functional well-being and head and
neck scales showed a statistically significant improvement over time (P<.001). After 12 months, 21 patients (81%) returned
to an oral diet, while 5 patients still needed tube feeding. For 23 patients
(88%), the quality and strength of the voice was more or less normal. Of the
18 patients who were employed before their treatment, 10 were able to return
to their job within 12 months. Xerostomia was reported by 17 patients (65%).
Further detailed analysis showed statistically significant differences in
pretreatment scores between the 1-year QOL group and the failure group, ie,
physical well-being, functional well-being, and the head and neck scales (P<.05). Differences in these groups with respect to
sex, age, tumor site, or stage could not be found.
Conclusion Given that only patients with locally (anatomic or functional) inoperable
stage IV disease were treated, the results are promising, underlining the
feasibility of the RADPLAT protocol.
INTRODUCTION
HEAD AND NECK cancer accounts for 7% of all malignancies in the Netherlands.1 Annually, around 2400 new patients are seen and approximately
600 of them present with advanced stage IV disease. Head and neck cancer is
mainly treated with surgery and/or radiotherapy. For the advanced cases, surgery
is the mainstay of treatment, often combined with postoperative radiotherapy.
However, surgery, often resulting in considerable anatomic changes, has a
major impact on the physical and psychosocial functioning of the patients.
Despite all recent advances in reconstructive surgery, patients often are
negative about resulting disfigurement and report problems with speaking,
eating, and social interactions, and feelings of anxiety and depression.2-7 These
problems are enhanced by the moderate to poor prognosis of advanced head and
neck cancer, often not exceeding a 5-year survival rate of approximately 25%.8 Locoregional cure rates are somewhat better, but a
significant proportion of patients will die within 2 years of the onset of
their disease because of the development of distant metastases or second primary
malignancies.9
The increasing awareness of the functional and psychosocial dysfunction
as a result of the often necessary, extensive surgical procedures stimulated
the quest for other, less debilitating therapeutic strategies for patients
with advanced head and neck cancer. This has led to the development of nonsurgical,
organ-preservation approaches, mainly combining chemotherapy and radiotherapy.
Until recently, induction and/or (neo)adjuvant chemotherapeutic regimens were
applied, but these have not resulted in an improved survival rate.10 There are some indications, however, that for laryngeal
and hypopharyngeal cancer, induction chemotherapy, followed by full-dose radiotherapy,
can result in a fair percentage of organ preservation without jeopardizing
the overall survival.11 More recently, it was
suggested that concomitant chemoradiation protocols might show an improvement
in overall survival.10 In particular, when
cisplatin-based chemotherapy was combined with radiotherapy results seemed
better. The chemotherapy is usually administered intravenously. However, Robbins
et al12-13 suggested that, when
administering cisplatin intra-arterially into the tumor region concomitantly
with full-dose radiotherapy (the RADPLAT protocol), surprisingly good results
in terms of locoregional control and disease-free survival could be obtained
in phase 2 studies. Furthermore, fair functional (swallowing and voice) results
were reported after treatment according to this protocol.14-15
In an attempt to confirm the feasibility of the treatment regimen and
the reported results, the RADPLAT treatment protocol was applied in a phase
2B trial in the Netherlands Cancer Institute, Amsterdam, in 79 patients with
advanced stage IV (mainly T4) head and neck carcinoma. In this article, we
report the results of the accompanying study evaluating the quality-of-life
(QOL) and functional outcomes of 50 consecutive patients entered in the first
1 years of the RADPLAT trial, of whom the first-year follow-up results
are available. Primary study end points, including survival, and locoregional
and distant control in the total study population (N = 79) will be presented
in a separate report.
PATIENTS AND METHODS
Fifty consecutive patients diagnosed as having local stage IV head and
neck cancer, enrolled in the RADPLAT protocol during the first 1 years,
participated in this QOL study. The study protocol was approved by the medical
ethical committee, and written informed consent was obtained from patients
before they entered the study.
Patient characteristics, including sites and stages, are shown in Table 1. Staging was accomplished according
to the International Union Against Cancer (Union Internationale Contre le
Cancer) staging system of 1997.16 Most patients
had extensive T4 disease (n = 43), whereas 7 patients had T3 disease involving
the base of tongue, in whom surgical resection would have required total glossectomy
or glossolaryngectomy (considered functionally inoperable because of the devastating
end result with respect to swallowing and speech). There were 37 men and 13
women with a mean age of 54 years (range, 41-70 years) and a follow-up of
1 year after initiating treatment. All patients had a history of excessive
smoking and (social) alcohol consumption. Only 1 patient indicated that he
had quit smoking 13 years before the cancer treatment. During the 1-year follow-up,
16 patients died of their disease or intercurrently (14 and 2 patients, respectively),
5 patients underwent salvage surgery, 2 patients could not be reached (returned
to the Netherlands Antilles), and 1 patient refused categorically to be interviewed
at the 6- and 12-month assessment points. For subgroup analysis, patients
were divided into 2 groups: the "failure" group and the "1-year QOL" group.
The patients who died within the first year or were treated for recurrent
or residual disease were combined into the failure group. The 26 patients
who completed the questionnaire at 12 months of follow-up were combined into
the 1-year QOL group. The data for the remaining 3 patients (who were unavailable
for follow-up) were used in the analysis, when available, but were excluded
in the failure and 1-year QOL subgroup analysis.
|
|
|
|
Table 1. Patient Characteristics (N = 50)
|
|
|
In this feasibility study, the protocol of Robbins et al17 was
followed. The treatment consists of cisplatin in a dose of 150 mg/m2 administered intra-arterially, with sodium thiosulfate given concurrently,
first as an intravenous bolus injection and then continuously as an intravenous
infusion, on days 2, 9, 16, and 23. The radiotherapy is given concomitantly
in 35 daily fractions of 200 rad (2 Gy) to a total dose of 7000 rad in 7 weeks.
Also, the QOL questionnaires incorporated in the aforementioned protocol were
applied, to allow better comparison with the results obtained in previously
reported studies. Therefore, the Dutch-Flemish translation of the Functional
Assessment of Cancer Therapy–Head and Neck questionnaire (FACT-H&N)
and the University of Washington (UW) questionnaire were used.18-20 The
interviews took place before treatment and at 3, 6, and 12 months after the
onset of the treatment. The FACT-H&N questionnaire consists of 28 general
and 11 head and neck–specific questions. Items, rated on a 0-to-4 point
Likert scale, are combined to describe patient QOL in 6 subscales: physical
well-being, social and family well-being, relationship with doctor, emotional
well-being, functional well-being, and head and neck–specific symptoms.
Higher scores on the various subscales represent a better QOL. To obtain additional,
more detailed information, the UW QOL questionnaire was used, consisting of
the following categories: pain, disfigurement, activity, recreation, employment,
eating (chewing and swallowing), saliva (amount and texture), taste, and speech.
All items are rated on a 5-point scale.20
For statistical analysis, the FACT-H&N items were combined into
a more limited set of multiple-item scales, according to Likert's method of
summated ratings.21 The reliability of the
scales was assessed with Cronbach  .22 Differences
over time within groups were tested with t tests
for paired observations, and the 2-sample t test
was used to compare differences between groups. The general linear models
procedure was applied for repeated measures. Correlations were assessed by
Pearson correlation coefficient. A 2-tailed P<.05
was considered statistically significant.
RESULTS
Both the FACT-H&N and UW scales have been used for the first time
in our institute. They are self-administered questionnaires. However, if the
choice of receiving assistance vs self-completion was left to the patient,
approximately three fourths of them asked for some help in completing the
questionnaires (reading and marking items per the patients' responses).
In applying the FACT-H&N scale, it appeared that the translation
into Dutch-Flemish was not always optimal (version October 9, 1996).19 For example, in items 1 and 3 of the physical well-being
subscale, a negation has been used in the sentence, making it very confusing
for the patient to answer. Furthermore, questions about losing hope and worrying
about dying (items 22 and 24 of the emotional well-being subscale) were rather
disturbing for the patients, especially in case of recurrence or metastases.
Since many patients used a tube feeding at some time during and/or after their
treatment, several questions on the head and neck subscale had to be skipped
at that time.
A common problem with the UW questionnaire concerned the item on the
amount of saliva. Especially immediately before and after treatment, many
patients had complaints of too much rather than too little saliva. This answer
could not be entered into the 5-point scale of this item. Also, the item assessing
voice quality was not quite suitable for our patient population. Patients
who have had this nonsurgical treatment do not have problems with the pronunciation
of certain words, but their voice can be hoarse or lacking in volume.
Despite these minor shortcomings, the reliability (Cronbach ),
assessing the internal consistency of the Likert scales of the FACT-H&N
questionnaire, was acceptable. In Table
2 the coefficient is shown at baseline (N = 50), at 6 months
(n = 37), and at 12 months (n = 26) after the start of treatment. In most
scales the coefficient was between 0.68 and 0.90. For the social well-being
subscale, only items 9 through 13 were used; item 14 was excluded, since many
patients did not answer that question if they did not have a partner. The
reliability of the head and neck scale was assessed across 9 items (exclusion
of items 42, smoking, and 43, drinking of alcohol).
|
|
|
|
Table 2. Reliability (Cronbach ) of the FACT-H&N Subscales*
|
|
|
Table 3 shows the results
of the FACT-H&N subscales for the 26 patients in the 1-year QOL group.
Three measuring points are included: pretreatment (baseline) and 3 months
(6 weeks after finishing treatment) and 12 months after onset of the treatment.
There was a slight decline at the 3-month interval and some improvement after
12 months (higher scores represent a better QOL). For the functional well-being
subscale and the head and neck subscale, these improvements are statistically
significant (P<.001).
|
|
|
|
Table 3. Results of the FACT-H&N Subscales (n = 26)*
|
|
|
SPECIFIC PHYSICAL, FUNCTIONAL, AND PSYCHOSOCIAL RESULTS
To provide more insight information, some functional (head and neck–related)
items, mainly based on the outcome of the UW questionnaire (n = 26), will
be shown in detail. Some expected problems, such as nausea, only sporadically
occurred. Six weeks after treatment, only 3 patients (12%) were still troubled
with nausea, and after 12 months no feelings of nausea were reported. Complaints
about pain 3 and 12 months after onset of treatment were as follows: at 3
months, 12 patients (46%) did not experience feelings of pain, 12 patients
(46%) needed regular (nonnarcotic) medication, and 2 patients (8%) still had
severe pain that had to be controlled by narcotics. At 12 months, 21 patients
(81%) did not experience any pain, while 5 patients (19%) required regular
(nonnarcotic) medication.
After 12 months, only 1 patient (female) reported that she was troubled
by her appearance; she had lost a lot of weight and her face had become very
thin and rather wrinkled. Eleven patients (42%) noted no changes and 14 patients
(54%) noted a minor change in appearance.
At the end of the observation period (12 months), 5 patients (19%) still
needed tube feeding, but 3 of them could combine this with drinking liquids.
As shown in Table 4, 16 patients
(62%) had little or no problems with mastication, while 10 patients (38%)
had moderate to very severe problems. Swallowing problems were present in
7 patients (27%). Seventeen patients (65%) complained about the decrease in
the amount of saliva, while 14 patients (54%) reported that the saliva was
"thicker than normal" or "dried in their mouth and/or on their lips." No statistically
significant correlations were found between the amount of saliva and mastication
or swallowing. The taste of food returned to normal in 18 patients (69%),
while for 6 patients (31%) some of the food still did not taste as it used
to.
|
|
|
|
Table 4. Frequencies of Problems With Mastication, Swallowing, Saliva,
and Taste After 12 Months (n = 26)
|
|
|
Concerning the voice quality and strength, based on item 38 (FACT-H&N),
16 patients (61%) reported that their voice was normal, 7 patients (27%) reported
somewhat normal, and in 3 patients (12%) the voice was still far from what
it used to be.
Twelve months after onset of treatment, 14 patients (54%) smoked again
or still, while 18 patients (69%) drank alcohol again or still (Table 5). There was a clear increase in smoking and drinking habits
over time, since at 3 months only 9 patients (35%) still smoked and only 7
(27%) still consumed alcohol.
|
|
|
|
Table 5. Smoking and Alcohol Habits After 12 Months (n = 26)
|
|
|
Of the 18 patients (69%) who had a job before their illness, 5 started
to work again after 6 months, while at 12 months a total of 10 patients were
back at their jobs. Thus, slightly more than half of the potential workers
(10/18) returned to their professional lives.
GROUP COMPARISON
The mean scores on the FACT-H&N questionnaire of the 1-year QOL
group (n = 26) and the failure group (n = 21) are shown in Table 6. The failure population scored lower on all subscales. These
differences, before treatment and at 6 months after onset of treatment, assessed
by a t test for group comparisons, were statistically
significant (P<.001 and P<.05,
respectively) for the physical (before treatment), emotional (6 months after
treatment), functional (before and 6 months after treatment), and the specific
head and neck symptom subscales (before and 6 months after treatment).
|
|
|
|
Table 6. Differences in Means at Baseline and 6 Months After Initiating
Treatment on the FACT-H&N Subscales Between the 1-Year QOL and Failure
Groups*
|
|
|
Differences in baseline means (Table
3 and Table 6) of the
1-year QOL group are explained by missing data in the different subscales
at the 12-month interview. If some items, for example, of the head and neck
subscale were not applicable for patients who still had tube feeding at that
time, the patient would be eliminated for the general linear models procedure
for repeated measures, resulting in a group number of 25 or 24 instead of
26. The baseline means in Table 6 are
from all 26 patients in the 1-year QOL group.
Statistical analysis of outcome by site was precluded because of the
small numbers of patients with the different disease sites.
COMMENT
The aim of this feasibility study was to assess the QOL and functional
outcome of patients with locally (anatomic or functional) inoperable stage
IV head and neck carcinoma during the first year after an intra-arterial cisplatin-based
chemoradiotherapy protocol (RADPLAT).12
As expected, the means of the different subscales showed a treatment-related
decline and an improvement in the period from 3 months to 1 year of follow-up
for the 1-year QOL group. The domains most affected by tumor and treatment,
such as functional well-being and head and neck–related symptoms, improved
significantly over time, exceeding pretreatment values. However, patients
with advanced head and neck cancer already begin their treatment with a compromised
QOL.15 The other subscales showed only minor
changes during the follow-up period, suggesting that patients' feelings of
emotional and social well-being were relatively independent of the treatment
and functional limitations, as was also demonstrated by List et al.23
Although the FACT-H&N questionnaire clearly assesses specific disease-
and treatment-related experiences of patients with head and neck cancer,24-26 the addition of the
UW questionnaire provided useful detailed information on specific areas such
as pain, disfigurement, mastication, swallowing, taste, xerostomia, and work.20 Pain, especially that experienced immediately after
treatment, could mostly be treated with nonnarcotic medication. As expected,
the problem of treatment-related disfigurement was minor after successful
organ preservation treatment: at 12 months, only 1 patient reported being
troubled by her appearance. Because of severe weight loss, her face had become
rather wrinkled.
Concerning the dysfunction domain, however, problems still exist. With
respect to eating problems, most patients regained more or less normal oral
feeding possibilities, but 5 patients (19%) at 1-year follow-up still needed
tube feeding, 3 of them because of mastication problems and 2 of them because
they could hardly swallow. Although formal assessment of dentition was not
included in this study, personal observations suggest that in some patients
the mastication problems were related to their dental situation, as was recently
also observed by others.23, 27 Optimizing
the fit of dentures has to wait until the oral adverse events, such as edema
and soreness, subside. Often, patients still were in the middle of their dental
rehabilitation program at the end of the first year. Another aspect in the
dysfunction domain, ie, the sense of taste, as expected, appeared to be severely
affected immediately after treatment. Many patients reported that their food
tasted like wet cardboard. During the follow-up period, in most patients the
normal sense of taste returned. Only 6 patients mentioned that some specific
types of food did not yet taste like they used to (eg, spicy food).
The most frequent complaint concerned xerostomia, which is one of the
most commonly encountered consequences of radiotherapy.23, 27-28 All
patients noted a decrease in the amount of saliva. Also, complaints about
the consistency (thicker, more sticky than it used to be) were frequently
reported.
With respect to voice, after 12 months the quality and the strength
of the voice in 3 patients still was severely compromised. They could hardly
make themselves understood. The sites of the tumors in these patients were
oropharynx, piriform sinus, and base of tongue, respectively. The voice results
after RADPLAT are more favorable than those after surgical treatment. Deleyiannis
et al29 compared surgically and nonsurgically
treated patients with advanced oropharyngeal cancer. They demonstrated that
the speech of 67% of the surgically treated patients deteriorated vs 43% of
the nonsurgically treated patients. Also, a previous study assessing consequences
of composite resection noted that two thirds of the patients reported reduced
intelligibility in face-to-face conversation, mostly because of rhinolalia
aperta.7
It is noteworthy that the recovery period after chemoradiation (RADPLAT)
is very different for each individual. In our study, of the 18 patients who
had a job before treatment, 5 already were at work after 6 months and another
5 at the 12-month assessment interview, while the remaining 8 patients needed
more time before they would be able to return to work. These individual differences
in time needed to recover are in contrast to what happens after surgery. Pauloski
et al28 found that the level of functioning
at the 1- and 3-month posthealing evaluations was characteristic of their
patients' status at 1 year after surgery. They found no progression in functioning
between 1 and 12 months after surgery.
Although self-reported data on alcohol consumption and tobacco use are
seldom reliable, items 42 and 43 of the FACT-H&N questionnaire will probably
distinguish between the smokers and nonsmokers and between the alcohol consumers
and nonconsumers. The results show that 14 of the 25 patients smoked again
(1 patient had quit smoking 13 years before the treatment), while 18 of the
26 drank alcohol again at 12 months. Most of them added that they drank and
smoked a lot less than they used to. According to the patients, alcohol was
consumed only during weekends and birthday parties. These disappointing data
show that, despite the information about the influence of continued smoking
(often in combination with alcohol) on the sequelae of treatment, prognosis,
and development of secondary malignancies, many patients continue to smoke
and drink.28, 30
Statistically significant pretreatment differences were found between
the 26 patients who were still alive at 12 months (the 1-year QOL group) and
those who died or had to undergo extensive surgery within 12 months (the failure
group) on the FACT-H&N physical, functional, and head and neck subscales.
This means that already at baseline the patients in the failure group presented
with lower pretreatment scores than the 1-year QOL group. This is in contrast
to a recent study by List et al,30 who noted
no statistically significant pretreatment differences between patients still
alive and without disease at 12 months and those who died within 12 months.
Further analysis showed that posttreatment scores of the survivors increase,
while the scores of the failure group continue to decrease. The decline in
those specific subscales (functional well-being and the head and neck subscales)
may explain the more prominent feelings of distress (emotional well-being
subscale) in the failure group. Patients often start the chemoradiation treatment
optimistically, but if during follow-up local recurrence or distant metastases
are diagnosed, obviously feelings of emotional well-being decrease.
CONCLUSIONS
As expected, the results show a decline on most subscales and specific
head and neck symptoms during and shortly after treatment. However, a statistically
significant improvement in the functional well-being and the head and neck
subscale is noted over time. The recovery period after RADPLAT therapy shows
a considerable variability between the individual patients. Ten of them returned
to their jobs within 12 months, while others needed more time to recover.
Considering the extent of the local disease (most patients having T4 lesions),
problems with eating recovered relatively well, with 80% of the patients returning
to a more or less normal oral diet. Xerostomia remains a residual complication
inherent in the nature of radiotherapy. For 23 patients (88%), the quality
and strength of the voice was more or less normal. Further analysis showed
already statistically significant differences in pretreatment scores between
the 1-year QOL group and the failure group. This concerns physical well-being,
functional well-being, and the head and neck subscales. Differences in these
groups with respect to sex, age, and tumor site or stage could not be found.
AUTHOR INFORMATION
Accepted for publication March 11, 2002.
This study was presented at the Fifth International Conference on Head
and Neck Cancer, San Francisco, Calif, July 30, 2000.
We thank Martin Muller, MSc, for his expert statistical advice.
Corresponding author: Annemieke H. Ackerstaff, PhD, The Netherlands
Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands (e-mail: a.ackerstaff{at}nki.nl).
From the Department of Otolaryngology, Head and Neck Surgery and Radiation
Oncology, The Netherlands Cancer Institute, Amsterdam.
REFERENCES
| |
1. Visser O, ed, Coebergh JWW, ed, Otter R, ed, Schouten LJ, ed. Head and Neck Tumours in the Netherlands 1989-1995. Utrecht: the Netherlands Cancer Registry; 1998.
2. Drettner B, Ahlbom A. Quality of life and state of health for patients with cancer in the
head and neck. Acta Otolaryngol. 1983;96:307-314.
PUBMED
3. Harwood AR, Rawlinson E. The quality of life of patients following treatment for laryngeal cancer. Int J Radiat Oncol Biol Phys. 1983;9:335-338.
ISI
| PUBMED
4. Breitbart W, Holland J. Psychosocial aspects of head and neck cancer. Semin Oncol. 1988;15:61-69.
ISI
| PUBMED
5. Dropkin MJ. Coping with disfigurement and dysfunction after head and neck cancer
surgery: a conceptual framework. Semin Oncol Nurs. 1989;5:213-219.
PUBMED
6. Balm AJM, Ackerstaff AH, Hilgers FJM, Gregor RT, Bos KE. Psychological aspects of major head and neck reconstructive surgery. Facial Plast Surg. 1995;11(2):89-96.
7. Ackerstaff AH, Lindenboom JAH, Balm AJM, Kroon FHM, Tan IB, Hilgers FJM. Structured assessment of the consequences of composite resection. Clin Otolaryngol. 1998;23:339-344.
FULL TEXT
|
ISI
| PUBMED
8. Hart AAM, Mak-Kregar S, Hilgers FJM, et al. The importance of correct stage grouping in oncology: results of a
nationwide study on oropharyngeal carcinoma in the Netherlands. Cancer. 1995;75:2656-2662.
FULL TEXT
|
ISI
| PUBMED
9. Hordijk GJ, de Jong JMA. Synchronous and metachronous tumours in patients with head and neck
cancer. J Laryngol Otol. 1983;97:619-621.
ISI
| PUBMED
10. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous
cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949-955.
ISI
| PUBMED
11. Wolf GT, Forrastiere A, Ang K, et al. Workshop report: organ preservation strategies in advanced head and
neck cancer—current status and future directions. Head Neck. 1999;21:689-693.
FULL TEXT
| PUBMED
12. Robbins KT, Vicario D, Seagren S, et al. Targeted supradose cisplatin chemoradiation protocol for advanced head
and neck cancer. Am J Surg. 1994;168:419-422.
FULL TEXT
|
ISI
| PUBMED
13. Robbins KT. The evolving role of combined modality therapy in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2000;126:265-269.
FREE FULL TEXT
14. Woodson GE, Rosen CA, Murry T, et al. Assessing vocal function after chemoradiation for advanced laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1996;122:858-864.
ABSTRACT
15. Murry T, Madasu R, Martin A, Robbins KT. Acute and chronic changes in swallowing and quality of life following
intraarterial chemoradiation for organ preservation in patients with advanced
head and neck cancer. Head Neck. 1998;20:31-37.
FULL TEXT
|
ISI
| PUBMED
16. UICC. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification
of Malignant Tumours. 4th ed. Berlin, Germany: Springer-Verlag; 1997.
17. Robbins KT, Kumar P, Regine WF, et al. Efficacy of targeted supradose cisplatin and concomitant radiation
therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys. 1997;38:263-271.
FULL TEXT
|
ISI
| PUBMED
18. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) Scale: development
and validation of the general measure. J Clin Oncol. 1993;11:570-579.
FREE FULL TEXT
19. Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy
(FACT) quality of life measurement system. Qual Life Res. 1996;5:309-320.
FULL TEXT
|
ISI
| PUBMED
20. Hassan SJ, Weymuller EA. Assessment of quality of life in head and neck cancer patients. Head Neck. 1993;15:485-496.
ISI
| PUBMED
21. Likert R. A technique for the measurements of attitudes. Arch Psychol. 1932;140:1-55.
22. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297-334.
FULL TEXT
|
ISI
23. List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients
on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol. 1999;17:1020-1028.
FREE FULL TEXT
24. Langius A, Björvell H, Lind MG. Functional status and coping in patients with oral and pharyngeal cancer
before and after surgery. Head Neck. 1994;16:559-568.
ISI
| PUBMED
25. List MA, D'Antonio LL, Siston A, Mumby P, Haraf D, Vokes E. The performance status scale for head and neck cancer patients and
the functional assessment of cancer therapy–head and neck scale. Cancer. 1996;77:2294-2301.
FULL TEXT
|
ISI
| PUBMED
26. D'Antonio LL, Zimmerman GJ, Cella CF, Long SA. Quality of life and functional status measures in patients with head
and neck cancer. Arch Otolaryngol Head Neck Surg. 1996;122:482-487.
ABSTRACT
27. Epsteinn JB, Emerton S, Kolbinson DA, et al. Quality of life and oral function following radiotherapy for head and
neck cancer. Head Neck. 1999;21:1-11.
FULL TEXT
|
ISI
| PUBMED
28. Pauloski BR, Logeman JA, Rademaker AW, et al. Speech and swallowing function after anterior tongue and floor of mouth
resection with distal flap reconstruction. J Speech Hear Res. 1993;36:267-276.
29. Deleyiannis FW-B, Weymuller EA, Coltrera MD. Quality of life of disease-free survivors of advanced (stage III or
IV) oropharyngeal cancer. Head Neck. 1997;19:466-473.
FULL TEXT
|
ISI
| PUBMED
30. List MA, Ritter-Sterr C, Lansky SB. A performance status scale for head and neck cancer patients. Cancer. 1990;66:564-569.
FULL TEXT
|
ISI
| PUBMED
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
RADPLAT: An Alternative to Surgery?
Alkureishi et al.
The Oncologist 2006;11:469-480.
ABSTRACT
| FULL TEXT
|
